Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam
Risdiplam (EVRYSDI) is approved for the treatment of patients with spinal muscular atrophy ≥ 2…
Certara2021 年 10 月 7 日
FDA’s Digital Transformation: The Future of Technology and How to Prepare
As Life-Science manufacturers embrace new technologies to speed time to market and products become more…
Certara2021 年 10 月 5 日
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
Certara2021 年 9 月 23 日
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often,…
Certara2021 年 9 月 23 日
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline
Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the…
Certara2021 年 8 月 16 日
